Abstract:The boronic acid group plays an important role in drug discovery. Following our discovery of a boronic acid analog of combretastatin A-4 (CA-4), a series of analogs featuring a boronic acid group on the C phenyl ring of CA-4 was synthesized and evaluated for cytotoxicity, as well as for their ability to inhibit tubulin polymerization, inhibit the binding of [ 3 H]colchicine to tubulin and cause depolymerization of cellular microtubules. Modifications on the C ring of CA-4, either eliminating the methoxy group or replacing the C phenyl ring with a pyridine ring, resulted in a reduced potency for inhibiting tubulin polymerization, colchicine binding and cytotoxic activities as compared to CA-4. Replacing the phenol group with a boronic acid group on the C ring of phenstatin led to a slight increase in cytotoxic potency but a decreased potency for inhibition of tubulin assembly and colchicine binding. Moreover, there was a significant decrease in activity by replacing the C phenyl ring with a pyridine ring. Our results indicate the critical importance of the methoxy group on the C ring as well as the importance of the C phenyl ring compared to a pyridine ring, despite the latter providing a nitrogen atom as a hydrogen bond donor/acceptor, which was predicted by molecular modeling to enhance interaction with the target. The decreased activities of our modified CA-4 boronic analogs may be attributed to weakened hydrogen bonding in our docking model based on the crystal structure of colchicine bound to αβ-tubulin. Notably, even though their effectiveness in inhibiting tubulin polymerization and colchicine binding and causing microtubule depolymerization in cells, the majority of these boronic acid analogs exhibited substantial cytotoxicity. This suggests that they may have additional cellular targets that contribute to their cytotoxicity, and this warrants further evaluation of these unique boronic acid compounds as potential anticancer agents.

Synthesis, in vitro, and in vivo evaluation of phosphate ester derivatives of combretastatin A-4

Development Of Novel Liposome-Encapsulated Combretastatin A4 Acylated Derivatives: Prodrug Approach For Improving Antitumor Efficacy

Water-Soluble Combretastatin A4 Phosphate Orally Delivered Via Composite Nanoparticles with Improved Inhibition Effect Toward S180 Tumors.

Design, Synthesis, Biological Evaluation and Cocrystal Structures with Tubulin of Chiral Β-Lactam Bridged Combretastatin A-4 Analogues As Potent Antitumor Agents.

Development of Combretastatin A-4 Analogues as Potential Anticancer Agents with Improved Aqueous Solubility

Synthesis and mechanistic studies of novel spin-labeled combretastatin derivatives as potential antineoplastic agents.

Targeted Polymeric Micelle System for Delivery of Combretastatin A4 to Tumor Vasculature in Vitro

Design, Synthesis, And Biological Evaluation Of Hydantoin Bridged Analogues Of Combretastatin A-4 As Potential Anticancer Agents

Design, synthesis of combretastatin A-4 piperazine derivatives as potential antitumor agents by inhibiting tubulin polymerization and inducing autophagy in HCT116 cells

Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling.

Reverse Micelles-In-Microspheres with Sustained Release of Water-Soluble Combretastatin A4 Phosphate for S180 Tumor Treatment

Synthesis and Biological Evaluation of 3-Alkyl-1,5-Diaryl-1H-Pyrazoles as Rigid Analogues of Combretastatin A-4 with Potent Antiproliferative Activity

4,5-Diaryl-3-Aminopyrazole Derivatives As Analogs Of Combretastatin A-4: Synthesis And Biological Evaluation

Design, synthesis, and anti-breast tumor activity of novel combretastatin A-4 analogues

Applying a Tripodal Hexaurea Receptor for Binding to an Antitumor Drug, Combretastatin-A4 Phosphate

Design, Synthesis and Antitumor Activity of Novel link-bridge and B-Ring Modified Combretastatin A-4 (CA-4) Analogues as Potent Antitubulin Agents

Practical and Green Synthesis of Combretastatin A-4 and Its Prodrug Ca4p Using Renewable Biomass-Based Starting Materials

Synthesis and structure-activity relationship of boronic acid bioisosteres of combretastatin A-4 as anticancer agents

Novel Combretastatin A-4 Derivative XN0502 Induces Cell Cycle Arrest and Apoptosis in A549 Cells.

Combretastatin A4 phosphate treatment induces vasculogenic mimicry formation of W256 breast carcinoma tumor in vitro and in vivo

In Vitro and in Vivo Studies of PEGylated Liposomes Co-Encapsulated Combretastatin A-4 and Doxorubicin